First patient enrolled in Phase II clinical trial of stem cell therapy for traumatic injuries
The first patient has enrolled in a Phase II clinical trial evaluating a stem cell therapy for the potential early treatment of traumatic injuries and their subsequent complications at The University of Texas Health Science Center at Houston (UTHealth).
The MATRICS-1 (MultiStem
® Administration for Trauma Related Inflammation and Complications) study is being conducted at Memorial Hermann-Texas Medical Center.
According to the Centers for Disease Control (CDC), trauma is the leading cause of death for individuals under the age of 45 and the third leading cause of death in the U.S., accounting for approximately 180,000 fatalities each year. It is also a leading cause of serious disability, especially among young people and members of the military that suffer trauma.
Thank you for reading!
Please log in, or sign up for a new account and purchase a subscription to continue reading.
We have used your information to see if you have a subscription with us, but did not find one. Please use the button below to verify an existing account or to purchase a new subscription.
Your current subscription does not provide access to this content. Please use the button below to manage your account.
Stem cell engineering used to identify gene signaling pathway linked to schizophrenia
Using human-induced pluripotent stem cells engineered from a single family s blood samples, a gene signaling pathway linked to a higher risk for developing schizophrenia was discovered by scientists at The University of Texas Health Science Center at Houston (UTHealth). The research was published in a recent issue of
Neuropsychopharmacology.
The signaling pathway researchers pinpointed is called phosphoinositide 3-kinase/glycogen synthase kinase 3 (PI3K/GSK3). Among the differentially expressed genes along the pathway was one called serum-glucocorticoid kinase 1 (SGK1), an inhibitor of GSK3 beta, which has been associated with schizophrenia.
December 18, 2020
COVID-19 has wreaked havoc around the globe, with more than 310,000 fatalities occurring in the United States alone. While much has been learned about the virus since it was first detected, the long-term effects on the health of coronavirus survivors may take years to understand. To find some answers, investigators from the Yale School of Medicine and partners across the country are launching a nationwide study of patients who were infected.
INSPIRE (Innovative Support for Patients with SARS COV-2 Infections Registry) is a Centers for Disease Control and Prevention-funded project led by Yale University with Rush University Medical Center; the University of Washington; the University of Texas Health Science Center at Houston; the University of Texas Southwestern Medical Center; the University of California, Los Angeles; the University of California, San Francisco; and Thomas Jefferson University. They will track 4,800 individuals to assess the longitudinal outcomes